Withdrawn: Company posted current access statement online; committed to additional disclosure as it refines & advances access plans for low & lower-middle income countries; will include key pricing decision factors in upcoming Responsibility Report & website.
Proposal asking the Board of Directors to report to shareholders on whether and how Regeneron’s receipt of public financial support for development and manufacture of preventives and/or therapeutics for COVID-19 is being, or will be, taken into account when making decisions that affect access to such products, such as setting prices.
We and selected third parties use cookies or similar technologies for technical purposes and, with your consent, for other purposes. You can consent to the use of such technologies by using the “Accept” button, by closing this notice, by scrolling this page, by interacting with any link or button outside of this notice or by continuing to browse otherwise.